NCT04964375 is a Phase 1 clinical trial of ABSK043 oral capsule in Neoplasms, sponsored by Abbisko Therapeutics Co, Ltd.

Who is sponsoring NCT04964375?

NCT04964375 is sponsored by Abbisko Therapeutics Co, Ltd.

What drugs are being tested in NCT04964375?

Interventions in NCT04964375: ABSK043 oral capsule.

Is NCT04964375 still recruiting?

NCT04964375 is currently status unknown. Last updated 27 April 2022.

Last reviewed 2022-04-27 · How we verify

NCT04964375

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor

Status unknown Phase 1 Last updated 27 April 2022

What this trial tests

Phase 1 trial testing ABSK043 oral capsule in Neoplasms in 60 participants. Status unknown.

Timeline

31 August 2021

Primary endpoint
23 October 2022

23 March 2023

Quick facts

Lead sponsor	Abbisko Therapeutics Co, Ltd
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	31 August 2021
Primary completion	23 October 2022
Estimated completion	23 March 2023
Sites	3 locations across Australia

Drugs / interventions tested

ABSK043 oral capsule — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →

Sponsor

Abbisko Therapeutics Co, Ltd — full company profile →

Who can join

18 and older, any sex, with Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumor. Preliminary antitumor activity will also be assessed. Investigate the pharmacodynamics (PD) effects and Investigate the metabolites of oral ABSK043

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

"Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity.
Xiao L, Zhang L, Guo C, Xin Q, et al · · 2024 · cited 37× · PMID 38923737 · DOI 10.1002/cac2.12579

Verify or expand the search:

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other Abbisko Therapeutics Co, Ltd trials

Trials by the same sponsor.

NCT07417189 — A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) · Phase 1, PHASE2 · recruiting
NCT07297875 — A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia · Phase 1, PHASE2 · not yet recruiting
NCT07164170 — A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib · Phase 2 · not yet recruiting
NCT07210996 — A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions i · Phase 1 · completed
NCT07288957 — A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04964375 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbisko Therapeutics Co, Ltd
Last refreshed: 27 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04964375.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing